FDA Says Anktiva Ads Overstated What the Bladder Cancer Drug Can Do: What Patients Should Know

If you recently saw claims that Anktiva can treat many kinds of cancer or even prevent cancer, the FDA says those claims go too far. For most readers, the key point is simple: Anktiva is approved for a narrow bladder cancer use, not as a general cancer treatment and not as a cancer-prevention shot.

That matters because drug ads, podcasts, and social clips can make a complicated treatment sound broader, easier, or more proven than it really is. For patients and families making hard decisions, the details matter.

What happened: FDA issued a warning letter

On March 13, 2026, the FDA sent a warning letter to ImmunityBio over a TV ad and a podcast discussion about Anktiva. The agency said the promotional materials were false or misleading because they suggested the drug could do much more than its approved use.

According to the FDA, the materials created the impression that Anktiva could treat all cancers or even prevent cancer after radiation exposure. The agency also said it was false to present Anktiva as a cancer vaccine.

For patients, this is more than a marketing dispute. When a drug is described in sweeping terms, people may assume it is broadly approved, strongly proven across many cancers, or much simpler to use than it is in real life.

What Anktiva is actually approved for

Anktiva is approved only in combination with BCG for adults with BCG-unresponsive non-muscle-invasive bladder cancer, also called NMIBC, with carcinoma in situ, or CIS, with or without papillary tumors.

That is a very specific group of patients. It does not mean the drug is approved for all bladder cancers. It also does not mean it is approved for lung cancer, pancreatic cancer, or cancer prevention. And it is not approved as a stand-alone treatment in this setting. The approved use is Anktiva with BCG.

Another practical point: this is not a routine shot given into the arm, vein, or muscle. The FDA-approved directions say it is for intravesical use only, meaning it is placed directly into the bladder.

Who this treatment is for: NMIBC, CIS, and BCG-unresponsive explained

These bladder cancer terms can sound overwhelming, so here is the plain-language version.

NMIBC means non-muscle-invasive bladder cancer. In plain English, that is early-stage bladder cancer that has not grown into the bladder’s muscle layer.

CIS, or carcinoma in situ, is a flat, high-risk cancer in the bladder lining. Even though it has not grown into the muscle, it is taken seriously because it can come back or worsen.

BCG-unresponsive means the cancer did not clear or came back after adequate treatment with BCG. BCG is a bladder treatment used for some early-stage bladder cancers. If it stops working well enough, doctors may discuss other options, and Anktiva plus BCG is one of them for this specific group.

This is why broad online claims can be misleading. Anktiva is not meant for the general public or even for everyone with bladder cancer. It is meant for a narrower group of adults whose cancer has already proved difficult to treat with BCG.

How treatment is given and where it fits in care

Anktiva is a liquid that is mixed with BCG and placed into the bladder through a catheter. The treatment stays in the bladder for about two hours, and then the patient empties the bladder.

That means this is a bladder-directed treatment, not a whole-body cancer shot. In general, bladder treatments placed directly into the bladder are used mainly for cancers that are still in or close to the inner lining of the bladder, not for cancers that have grown deep into the bladder wall or spread elsewhere.

The treatment schedule can also be more involved than a short ad might suggest. The initial course is once a week for six weeks. If there is still evidence of cancer at three months, another six weekly treatments may be given. If the patient has a complete response, additional maintenance treatments may continue over many months.

In the approval study, patients had already undergone bladder tumor removal as part of their care before starting this regimen. So this is not usually a simple one-step treatment.

What the evidence showed and an important limitation

The FDA says Anktiva’s approval was based on one open-label, single-arm, multicenter clinical trial. In plain language, that means everyone in the main study group got the treatment, there was no randomized comparison group, and both doctors and patients knew what treatment was being given.

The trial included 88 adults at 22 sites in the United States. The FDA evaluated efficacy in 77 patients who were considered suitable for response analysis.

In the FDA’s summary, 62% of evaluable patients had no evidence of bladder cancer at some point during treatment. Among the patients who had that complete response, 58% remained in response for more than one year, and 40% remained in response for more than two years.

Those results may sound encouraging, but the study design is important context. A single-arm study can support approval, especially in a hard-to-treat setting, but it does not provide the same level of certainty as a randomized head-to-head trial. It cannot tell readers that the drug works across many cancers, works better than every alternative, or should be viewed as a stand-alone cure.

The FDA warning letter also pointed to another important detail: a study group that looked at Anktiva alone in the same disease setting was stopped early for futility. In everyday terms, that means the single-agent approach was not performing well enough. That is one reason it would be misleading to present Anktiva as if it were approved by itself for this bladder cancer use.

Side effects, treatment burden, and why delayed care can matter

Like many bladder-directed treatments, Anktiva plus BCG can irritate the urinary tract and cause flu-like symptoms.

Common side effects reported by the FDA include pain or burning with urination, blood in the urine, frequent urination, urgency, urinary tract infection, chills, fever, bladder irritation, fatigue, nausea, and diarrhea. Some patients also had lab changes such as increased creatinine.

These side effects are not trivial. They can interrupt treatment, add more clinic visits, and require close follow-up. Patients should go into conversations about Anktiva understanding that this is not a low-effort or side-effect-free option.

The FDA also highlights an especially serious issue: delaying cystectomy, which is surgery to remove the bladder, can allow the cancer to spread into the bladder muscle or to other parts of the body, and that can be fatal. This does not mean every patient should have immediate bladder removal. It does mean treatment decisions should be made carefully with a urologist or oncology team, especially if a bladder-sparing approach is not working.

What patients should do if they see broad cancer claims online

When a cancer ad sounds sweeping or simple, pause and check a few basics:

Is the claim talking about the drug’s actual FDA-approved use, or something much broader?
Is the treatment approved alone, or only in combination with another therapy?
How is the drug really given in practice?
What type of study supports the claim: a randomized trial, a single-arm study, or something even earlier?
Are the risks and side effects being discussed clearly, or mostly skipped?

If you or a family member has bladder cancer, a good next step is to ask the treating team direct questions such as: Is this drug approved for my exact diagnosis? Would it be given with BCG? What are the likely benefits, side effects, and alternatives? When would surgery still need to be considered?

And if you have blood in the urine, pain with urination, frequent urination, or other ongoing urinary symptoms, do not rely on marketing claims online. Blood in the urine is a common warning sign of bladder cancer, although it can also have other causes. Persistent urinary symptoms deserve medical evaluation.

What this means for readers

The practical takeaway is straightforward. Anktiva is a real FDA-approved treatment, but for a specific bladder cancer setting: adults with BCG-unresponsive non-muscle-invasive bladder cancer with CIS, with or without papillary tumors, and it is used with BCG inside the bladder. That is very different from saying it treats all cancers or prevents cancer.

For readers trying to make sense of cancer news, the safest habit is to match big claims against the actual FDA label and the kind of study behind them. That extra step can help separate useful information from marketing that sounds larger than the evidence.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.